Point Therapeutics to present data supporting anti-tumor drug talabostat

By Angela McDaniels

Seattle, May 31 - Point Therapeutics Inc. said new data evaluating talabostat's anti-tumor activity in phase 2 studies in advanced chronic lymphocytic leukemia, metastatic melanoma, metastatic colorectal cancer and in a preclinical osteosarcoma model will be presented in four presentations at the 42nd American Society of Clinical Oncology Annual Meeting in Atlanta on June 3-5.

Point Therapeutics' clinical program includes two phase 3 trials in metastatic non-small cell lung cancer and phase 2 trials in advanced chronic lymphocytic leukemia, metastatic melanoma and metastatic pancreatic cancer.

"We believe that these presentations underscore talabostat's potential use in a wide range of cancers," president and chief executive officer Don Kiepert said in a company news release.

Talabostat is an oral, targeted dipeptidyl peptidase inhibitor in clinical development for potential use in oncology. Dipeptidyl peptidase inhibitors are enzymes that appear to regulate several different physiological processes including those involved in tumor growth and host responses to cancer, type 2 diabetes and immune responses to vaccines, according to the release.

The company said it believes that talabostat employs a novel dual mechanism of action by targeting a dipeptidyl peptidase inhibitor called fibroblast activation protein that is uniquely expressed in the connective tissue of a tumor, while concurrently stimulating the immune system.

Point is a Boston-based biopharmaceutical company developing a portfolio of dipeptidyl peptidase inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.